Cancer immunotherapy

Ramon Alemany Bonastre / Josep Maria Piulats Rodriguez

PRINCIPAL INVESTIGATORS
  • Rafael Moreno Olié
CLINICAL RESEARCHERS
  • Oscar Buisán Rueda
  • Claudio Rocha Calderon
POSTDOCTORAL RESEARCHERS
  • Marcel Costa Garcia
  • Maria Dolores Lopez Robles
  • Rafael Moreno Olié
  • Gabriel Espinosa Carrasco
PREDOCTORAL RESEARCHERS
  • Luis Paul Del Carpio Huerta
  • Laura Moya Borrego
  • Sebastian Ciro Carne Martin
  • Pau Fiol Mata
  • Juan Antonio Marin Jimenez
SCIENTIFIC SUPPORT
  • Carles Codony Servat
  • Silvia Torres Manjon
  • Paz Moreno Serrano
  • Ana Maria Torrent Moreno
  • Ainhoa Muñoz Metrino
Cancer
Oncobell

Scientific production

20

PAPERS

Average IF: 27,733

7

LED PAPERS

Average IF: 13,243

8 PUBLICATIONS IN FIRST DECILE

14 PUBLICATIONS IN FIRST QUARTILE

17 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Fizazi,K;Piulats,JM;Reaume,MN;Ostler,P;McDermott,R;Gingerich,JR;Pintus,E et al, Rucaparib or Physician’s Choice in Metastatic Prostate Cancer., N. Engl. J. Med., 2023;388(8):719-732, doi:10.1056/NEJMoa2214676
  • Hassel,JC;Piperno Neumann,S;Rutkowski,P;Baurain,JF;Schlaak,M;Butler,MO;Sullivan,RJ et al, Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma, N. Engl. J. Med., 2023;389(24):2256-2266, doi:10.1056/NEJMoa2304753
  • Piulats,JM;Watkins,C;Costa García,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis., Ann. Oncol., 2023;doi:10.1016/j.annonc.2023.11.013
  • Piulats,JM;Watkins,C;Costa García,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis., Ann. Oncol., 2023;doi:10.1016/j.annonc.2023.11.013
  • Garofalo,M;Wieczorek,M;Anders,I;Staniszewska,M;Lazniewski,M;Prygiel,M;Zasada,AA et al, Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model, Front. Oncol., 2023;131259314-1259314, doi:10.3389/fonc.2023.1259314

Research highlights

PROJECTS

4 Granted Competitive project
15 Ongoing Competitive projects

4 Started clinical trials
25 Ongoing clinical trials
4 Ongoing non competitive project

INNOVATION

2 Patents
2 Licenses
 

NETWORKS

RICORS
AGAUR SGR GRC
Adenonet

 

Selected projects

  • 20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM). Instituto de Salud Carlos III (ISCIII). Budget: 694.346,29€. 2020-2025. PI: Piulats Rodríguez, Josep María.
  • 21FIS038. Venciendo la resistencia a la inmunoterapia en tumores no antigéncios ni inmunogénicos usando el cáncer de próstata como modelo. El estudio HEAT-CRPC. Instituto de Salud Carlos III (ISCIII). Budget: 133.100€. 2021-2025. PI: Piulats Rodríguez, Josep María.
  • FIS21131. RICORS TERAV. Instituto de Salud Carlos III (ISCIII). Budget: 169.412,1€. 2022-2024. PI: Alemany Bonastre, Ramón.
  • 2022-160-1. ESTUDIO FASE II, ABIERTO DE LA EFICACIA PRELIMINAR DE SITRAVATINIB EN COMBINACIÓN CON TISLELIZUMAB EN PACIENTES CON MELANOMA METASTÁSICO UVEAL CON HEPÁTICAS METÁSTASIS. Grupo Español Multidisciplinar de Melanoma (GEM). Budget: 5.000€. 2022- . PI: Piulats Rodríguez, Josep María.
  • 18ACL149. A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN IN PATIENTS WITH ADVANCED UVEALMELANOMA. Immunocore Ireland Limited. Budget: 154.384€. 2018- . PI: Piulats Rodríguez, Josep María.